1. Pink Sheet
  2. >>Archive

Up Close With Russian Investor Rusnano: A Q&A With Anatoly Chubais

 
• By Stacy Lawrence

In 2007, the Russian government committed $10 billion to invest in nanotechnology. About half of that has been invested, with little to show for it so far. After a recent shake-up, Rusnano is looking to prove itself and attract the private investors that could allow it eventually to privatize.

Six years into its mission, state-backed Russian investment group Rusnano has committed roughly $5 billion of its $10 billion fund to investments in more than 85 companies and 10 funds.

To publicize its successes the Russian Innovation Center – comprised of three Russian-backed initiatives: mid-stage, nano-focused Rusnano, early stage venture investor Russian Venture Capital (RVC) and the university and technology transfer arm, the Skolkovo Foundation – held their second annual bicoastal U.S. tour

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.